Management of cutaneous toxicity induced by epidermal growth factor receptor inhibitors (EGFR-I) in squamous cell carcinomas of the head and neck, colorectal or lung cancer

EGFR-I frequently induce skin or appendage toxicities that may impact patient’s quality of life and lead to reduction in the dose or event the discontinuation of the anti-tumor treatment. Wound healing products can be used to manage cutaneous toxicities in association with pharmacological measures.